This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by VINIK, A. I. Articles by CHO, K. Search for Related Content PubMed PubMed Citation Articles by VINIK, A. I. Articles by CHO, K.

Plasma Substance-P in Neuroendocrine Tumors and Idiopathic Flushing: The Value of Pentagastrin Stimulation Tests and the Effects of Somatostatin Analog^*

Departments of Internal Medicine, Surgery, Pathology, and Radiology, University of Michigan Medical Center Ann Arbor, Michigan 48109

Address requests for reprints to: Aaron I. Vinik, M.D., Diabetes Institutes, Eastern Virginia Medical School, Norfolk, VA 23510.

We examined the role of the potent vasoactive kinin substance-P (SP) in flushing derived from various causes. SP was measured in plasma after acetone/ether extraction using an antiserum directed at the carboxy-terminal 5–11 amino acid region of undecapeptide SP. The antiserum had less than 1% cross-reaction with the other neurokinins, neurokinin-A and neuropeptide-K, that derive from the β-preprotachykinin gene and share carboxy-terminal residues. Basal and pentagastrinstimulated SP levels were measured in 22 healthy controls, 11 patients with histologically proven carcinoid tumors, 8 patients with tumors other than carcinoid, and 7 patients with idiopathic flushing (IF). Basal SP levels were less than 10 pg/mL in normal subjects. All patients with midgut carcinoid tumors had SP levels greater than 25 pg/mL, as did 7 of 8 patients with noncarcinoid tumors and 5 of 7 patients with IF. Using 50 pg/mL as the cutoff point, the sensitivity was 63% for detection of a tumor, and 100% of nontumor patients were excluded.

Pentagastrin administration uniformly induced flushing and caused a rise in SP levels greater than 150 pg/mL in 5 of 10 patients with carcinoid tumors, 3 of 8 with noncarcinoid tumors, and 0 of 7 with IF, i.e. a SP rise of more than 100 pg/mL suggests a tumor.

Administration of somatostatin (150 µg) 0.5 h before the pentagastrin abolished flushing in all carcinoid patients and reduced SP levels, but not into the normal range. Long term treatment with SMS significantly reduced flushing and lowered SP levels, but did not restore these to normal.

We conclude that 90% of patients with carcinoid/noncarcinoid tumor have raised COOH-terminal SP levels. A basal level above 50 pg/mL or a pentagastrin-stimulated rise of more than 100 pg/mL distinguishes carcinoid from IF. The dissociation between SP concentrations and flushing suggests that SP may not be the only kinin involved in the flushing associated with carcinoid tumors.

^* This work was supported by grants 1R01-CA-69177-01A2 to the Clinical Research Center (RR-00042).

Received August 14, 1989.

This article has been cited by other articles:

				C. M. Korse, B. G. Taal, C. A. de Groot, R. H. Bakker, and J. M.G. Bonfrer Chromogranin-A and N-Terminal Pro-Brain Natriuretic Peptide: An Excellent Pair of Biomarkers for Diagnostics in Patients With Neuroendocrine Tumor J. Clin. Oncol., September 10, 2009; 27(26): 4293 - 4299. [Abstract] [Full Text] [PDF]

				M. Hejna, M. Schmidinger, and M. Raderer The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann. Onc., May 1, 2002; 13(5): 653 - 668. [Abstract] [Full Text] [PDF]